Neuro-Innovators
Clinical-stage pharmaceutical company developing combination drug therapies engineered to enhance neuroplasticity for functional brain restoration. Focused initial development on oral multi-drug formulations to improve motor recovery in chronic stroke survivors through investigator-led clinical studies and a regulatory strategy relying on repurposed, FDA-approved compounds.
Industries
N/A
Nr. of Employees
small (1-50)
Neuro-Innovators
Headquartered in Pittsburgh, Pennsylvania; Sewickley, PA 15143 (press release contact address)
Products
Oral three-drug combination therapy (lead clinical candidate)
A once-daily oral combination of three FDA-approved, brain-penetrant compounds engineered to enhance neuroplasticity when administered alongside intensive rehabilitation to improve motor recovery in chronic stroke survivors.
Oral three-drug combination therapy (lead clinical candidate)
A once-daily oral combination of three FDA-approved, brain-penetrant compounds engineered to enhance neuroplasticity when administered alongside intensive rehabilitation to improve motor recovery in chronic stroke survivors.
Services
Partnerships with rehabilitation hospitals and investigator teams to run proof-of-concept clinical studies integrating pharmacologic interventions with standard rehabilitation protocols.
Partnerships with rehabilitation hospitals and investigator teams to run proof-of-concept clinical studies integrating pharmacologic interventions with standard rehabilitation protocols.
Expertise Areas
- Clinical trial management (investigator-initiated studies)
- Neuropharmacology and polypharmacy design
- Regulatory strategy (505(b)(2) / FDA fast-track)
- Biomarker development and longitudinal clinical analytics
Key Technologies
- Combination/polypharmacy therapy design
- In-silico compound screening
- Blood-based biomarker assays
- Robot-assisted neurorehabilitation
News & Updates
Press release announcing collaboration with Spaulding Rehabilitation Hospital to run a Phase 2(a) proof-of-concept study of a three-drug combination therapy in chronic stroke patients.
Pittsburgh Post-Gazette article covering the collaboration with a Boston hospital to test a three-drug combination for stroke rehabilitation and describing study design and market context.
Local TV coverage reporting on the research agreement with Spaulding Rehabilitation Hospital and describing an eight-week rehab protocol for 40 study participants.
Company CEO interview discussing the company concept and plans.
Interview/article that describes company strategy, team building, and plans including timeline expectations for Phase 2(a) completion.
Provisional patent filings (with PCT filings) covering drug+device methods, combinatorial drug methods using a seven-mechanism matrix, and composition/formulation protection for the lead combination therapy.
Press release announcing collaboration with Spaulding Rehabilitation Hospital to run a Phase 2(a) proof-of-concept study of a three-drug combination therapy in chronic stroke patients.
Pittsburgh Post-Gazette article covering the collaboration with a Boston hospital to test a three-drug combination for stroke rehabilitation and describing study design and market context.
Local TV coverage reporting on the research agreement with Spaulding Rehabilitation Hospital and describing an eight-week rehab protocol for 40 study participants.
Company CEO interview discussing the company concept and plans.
Interview/article that describes company strategy, team building, and plans including timeline expectations for Phase 2(a) completion.
Provisional patent filings (with PCT filings) covering drug+device methods, combinatorial drug methods using a seven-mechanism matrix, and composition/formulation protection for the lead combination therapy.